Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Ironwood Pharmaceuticals announced it will present data highlighting the burden of total parenteral nutrition in Short Bowel Syndrome (SBS) at the Digestive Disease Week 2026 meeting. The company will also feature long-term safety and tolerability data from the STARS clinical trial program for apraglutide, alongside multiple analyses of LINZESS (linaclotide) efficacy and safety in IBS-C, CIC, and pediatric populations.
Key figures
- Landmark survey participants
- 336
- Estimated sbs if patients us eu japan
- 18000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.